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Abstract
Background: Although radiotherapy is a key component of curative-intent treatment for locally advanced, unresectable
non-small cell lung cancer (NSCLC), it can be associated with substantial pulmonary toxicity in some patients. Current
radiotherapy planning techniques aim to minimize the radiation dose to the lungs, without accounting for regional
variations in lung function. Many patients, particularly smokers, can have substantial regional differences in pulmonary
ventilation patterns, and it has been hypothesized that preferential avoidance of functional lung during radiotherapy
may reduce toxicity. Although several investigators have shown that functional lung can be identified using advanced
imaging techniques and/or demonstrated the feasibility and theoretical advantages of avoiding functional lung during
radiotherapy, to our knowledge this premise has never been tested via a prospective randomized clinical trial.
Methods/Design: Eligible patients will have Stage III NSCLC with intent to receive concurrent chemoradiotherapy
(CRT). Every patient will undergo a pre-treatment functional lung imaging study using hyperpolarized 3He MRI in order
to identify the spatial distribution of normally-ventilated lung. Before randomization, two clinically-approved radiotherapy
plans will be devised for all patients on trial, termed standard and avoidance. The standard plan will be designed without
reference to the functional state of the lung, while the avoidance plan will be optimized such that dose to functional lung
is as low as reasonably achievable. Patients will then be randomized in a 1:1 ratio to receive either the standard or the
avoidance plan, with both the physician and the patient blinded to the randomization results. This study aims to accrue a
total of 64 patients within two years. The primary endpoint will be a pulmonary quality of life (QOL) assessment at
3 months post-treatment, measured using the functional assessment of cancer therapy–lung cancer subscale. Secondary
endpoints include: pulmonary QOL at other time-points, provider-reported toxicity, overall survival, progression-free
survival, and quality-adjusted survival.
Discussion: This randomized, double-blind trial will comprehensively assess the impact of functional lung avoidance on
pulmonary toxicity and quality of life in patients receiving concurrent CRT for locally advanced NSCLC.
Trial registration: Clinicaltrials.gov identifier: NCT02002052.
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Background
Radiation induced lung injury
Lung cancer is the most common cause of cancer death in
men and women worldwide [1]. The large majority of lung
cancer patients present with non-small cell lung cancer
(NSCLC), and of these, approximately 30% present with
locally advanced (stage III) disease. The current standard
of care for locally advanced unresectable NSCLC is con-
current chemotherapy (CRT) with curative intent [2,3].
Survival improvements of concurrent CRT over sequential
CRT have been well-defined after multiple randomized tri-
als, with concurrent CRT conferring a 10% overall survival
benefit at two years [4,5]; however, such treatment is asso-
ciated with an increased risk of radiation-induced lung in-
jury (RILI), including radiation pneumonitis (RP).
Clinically symptomatic RP occurs in 30-40% of pa-
tients after concurrent CRT and can have a major impact
on quality of life, sometimes resulting in oxygen depend-
ence, and in severe cases is fatal [6,7]. Several factors are
currently used to attempt to predict RP and to mitigate
risk. Most of these predictive factors are metrics of the
radiation dose delivered to normal lung, such as the vol-
ume of lung receiving ≥20 Gy of radiation, the mean
lung dose and the dose per fraction of radiation. For ex-
ample, a recent meta-analysis found that the volume of
lung receiving at least 20 Gy (V20) is the best individual
predictor of RP risk; a V20 > 40% is associated with a
35% risk of symptomatic RP, and >3% risk of fatal RP
[7], supporting several previous single-institution studies
[8] and a systematic review [6].
The risk of RP limits the radiotherapy dose that can be
safely delivered. Although numerous modelling studies
have indicated that higher doses of radiotherapy should be
associated with improved oncologic outcomes, random-
ized data have shown that dose escalation leads to excess
lung toxicity. The recent landmark RTOG 0617 random-
ized trial compared standard vs. high dose radiotherapy
(60 Gy vs. 74 Gy), with concurrent chemotherapy, for lo-
cally advanced NSCLC. Overall survival at 18-months was
66.9% in the 60-Gy arm and 53.9% in the 74-Gy arm (p <
0.001), indicating inferior survival with dose-escalation [9].
Toxicity outcomes from RTOG 0617, as scored by the
health-care providers, did not initially appear to explain the
inferior survival in the high-dose arm. Although there were
more deaths due to radiation pneumonitis in the high-dose
arm (5% vs. 1%) this did not meet statistical significance
and only accounted for a small proportion of the overall
survival difference between the two arms. However, pa-
tient-reported outcomes indicated a different toxicity profile;
respiratory toxicity was common and was not often de-
tected by the health-care providers. In the high-dose arm,
49% of patients exhibited a clinically-meaningful decline in
the pulmonary quality of life (QOL) at 3-months, compared
to 31% of patients in the low-dose arm (p = 0.024).
Pulmonary QOL was also an important survival metric
overall. Baseline QOL predicted for overall survival (OS) in
multivariable analysis, more so than stage, performance sta-
tus and other conventional prognostic factors [9].
In summary, for patients treated with standard concur-
rent CRT for locally advanced lung cancer, RP is a major
source of morbidity, impairs quality of life, and can re-
sult in treatment-related death. RP also limits the dose
of radiotherapy that can be safely delivered, and cur-
rently precludes radiotherapy dose escalation. RP is not
well-ascertained by healthcare providers; in contrast,
patient-reported QOL outcomes appear to be a powerful
tool to capture pulmonary toxicity outcomes [9]. Clearly,
better methods are needed to reduce pulmonary toxicity
for patients undergoing concurrent CRT for lung cancer.
Functional lung avoidance
At present, radiation treatment planning for advanced
lung cancer is based upon minimizing radiation dose to
the total lung, regardless of the degree of function at any
particular point within that lung. This approach does not
account for the fact that lung tissue can be heterogeneous,
especially in smokers, whose lungs are frequently charac-
terized by large regions of unventilated parenchyma such
as bullae. Ideally, radiotherapy treatment planning should
be able to exploit these regional differences in lung func-
tion by minimising dose to the more highly functional
lung while favouring radiation deposition in areas of less
highly-functioning or non-functioning lung.
Over the last decade, functional measurements and maps
obtained from thoracic imaging have been evaluated for use
in lung cancer radiation therapy planning with single pho-
ton emission computed tomography (SPECT) [10,11], high
resolution four-dimensional x-ray computed tomography
(4DCT) [12,13], and hyperpolarized noble gas magnetic
resonance imaging (MRI) [14,15]. All of these techniques
potentially facilitate the delineation of regional pulmonary
function for lung cancer radiation treatment planning,
resulting in reduced radiation dose to well-functioning lung
without dose decreases to the treatment target volume
[11,15,16]. However, it is not clear which of these is
optimum, as each has its own merits and drawbacks. For ex-
ample, one of the most widely studied techniques is SPECT.
Although the incorporation of SPECT for lung cancer radi-
ation therapy planning has been promising, there are some
inherent limitations that may preclude its routine clinical
use, mainly related to image artefacts stemming from radi-
olabelled tracers depositing in the major airways [17], requir-
ing significant post-processing to remove, and sometimes
resulting in distortion of the underlying ventilation signal.
Hyperpolarized noble gas MRI
Hyperpolarized 3He MRI provides an alternative to ven-
tilation SPECT [15,18]. 3He MRI provides relatively high
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spatial and temporal resolution of respiratory function,
can be used safely in a wide variety of respiratory patients
and does not release ionizing radiation [19]. Although 3He
MRI has several inherent advantages, it will not likely
achieve widespread clinical use due to cost and a limited
global supply of 3He gas for research purposes. Several al-
ternative imaging techniques appear promising and are
expected to be available for widespread clinical use in the
future, including 129Xe MRI, which is currently less well-
developed than 3He MRI [20], 1H Fourier decomposition
methods [21], and 4DCT-based ventilation mapping [22].
If the benefits of functional lung avoidance can be demon-
strated now using 3He MRI, then other, more easily ac-
cessible ventilation imaging modalities (e.g. 4DCT and
129Xe MRI) may allow for more widespread implementa-
tion of functional lung avoidance radiotherapy in future.
Methods/design
Objectives
General objective
To determine if functional lung avoidance based on 3He
MRI improves quality of life outcomes for patients with
NSCLC undergoing concurrent CRT.
Primary endpoint
 Pulmonary QOL 3-months post-treatment
○Measured using the Functional Assessment of
Cancer Therapy—Lung Cancer Subscale (FACT-LCS)
Secondary endpoints
 Pulmonary QOL at other time-points
○ Measured using the FACT-LCS
 Other QOL scores
○ FACT—Trial Outcomes Index (FACT-TOI)
○ FACT—Lung (FACT-L) and subscales
 Provider-reported toxicity (including RP and
esophagitis)
○ Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
 Overall Survival
○ Defined as time from randomization to death
from any cause
 Progression-free survival
○ Time from randomization to disease progression
at any site or death
○ Progression defined according to RECIST 1.1
 Quality-Adjusted Survival (based on EQ-5D)
Study design
This study is a double-blinded randomized controlled
trial (Figure 1).
Patient selection
Inclusion criteria
 Age 18 or older
 Willing to provide informed consent
 ECOG performance status 0-2
 Histologically confirmed non-small cell lung
carcinoma
 Locally advanced Stage IIIA or IIIB lung carcinoma
according to AJCC 7th edition
 History of at least 10-pack-years of smoking
 Ambulatory and able to perform the Six Minute
Walk Test (6MWT)
 FEV1 ≥ 750 ml or ≥30% predicted
 Not undergoing surgical resection
 Assessment by medical oncologist and radiation
oncologist, with adequate bone marrow, hepatic and
renal function for administration of platinum-based
chemotherapy, as determined by the treating
physicians
Exclusion criteria
 Subject has an implanted mechanically, electrically
or magnetically activated device or any metal in
their body which cannot be removed, including but
not limited to pacemakers, neurostimulators,
biostimulators, implanted insulin pumps, aneurysm
clips, bioprosthesis, artificial limb, metallic
fragment or foreign body, shunt, surgical staples
(including clips or metallic sutures and/or ear
implants)
 In the investigator’s opinion, subject suffers from
any physical, psychological or other condition(s)
that might prevent performance of the MRI, such as
severe claustrophobia.
 Serious medical comorbidities (such as unstable
angina, sepsis) or other contraindications to
radiotherapy or chemotherapy
 Prior history of lung cancer within 5 years
 Prior thoracic radiation at any time
 Metastatic disease. Patients who present with
oligometastatic disease where all metastases
have been ablated (with surgery or radiotherapy)
are candidates if they are receiving concurrent
CRT to the thoracic disease with curative
intent
 Inability to attend full course of radiotherapy or
follow-up visits
 Pregnant or lactating women
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Pre-treatment evaluation
 History and physical examination by a radiation
oncologist and medical oncologist within 12 weeks
prior to enrolment onto study
 Histological confirmation of non-small cell
carcinoma
 Standard staging within 12 weeks prior to initiation
of chemotherapy including:
○ CT chest and upper abdomen
○ Whole body FDG-PET-CT scan (currently
funded for stage III NSCLC in Ontario)
○ CT head or MRI head
 Pulmonary function tests within 12 weeks of
initiation of radiotherapy showing adequate FEV1:
the best value obtained pre- or post-bronchodilator
must be ≥750 ml or ≥30% predicted
 Bloodwork: CBC with differential, Hemoglobin,
AST, ALT, bilirubin, creatinine should be done
before 1st cycle of chemotherapy. If any tests are
missed they must be done prior to start of radiation.
 Pregnancy test for women of child-bearing age
Study visits
Subjects will visit the research center three times: pre-
treatment, three months post-treatment, and 12 months
post-treatment. 3He MRI and non-contrast chest CT will
be performed on the first visit only. Subjects will undergo
pulmonary function tests, Forced Oscillation Technique,
6MWT, and QOL questionnaires at each visit.
Pulmonary function tests
Full pulmonary function tests including spirometry, pleth-
ysmography and diffusing capacity of carbon monoxide
(DLCO) will be performed according to the joint American
Thoracic Society/European Respiratory Society (ATS/ERS)
guidelines [23-27] using the MedGraphics (Elite Series,
MedGraphics Corporation, St. Paul, MN USA) whole-
body plethysmograph and/or ndd EasyOne Spirometer
(ndd Medical Technologies Inc., Andover, MA USA).
Airwave oscillometry will be performed using the Tre-
moFlo™ (THORASYS Thoracic Medical Systems, Halifax,
NS). Airwave oscillometry measures the mechanics of the
respiratory system and evaluates lung function without
patient effort by superimposing a gentle multi-frequency
airwave onto the patient’s respiratory airflow. Patients
breathe normally throughout the measurement sequence
for less than a minute via a disposable mouthpiece.
Six minute walk test
Subjects will perform the 6MWTaccording to ATS guide-
lines [28]. Subjects will rate their dyspnea and overall fa-
tigue at baseline and at the end of the exercise using the
Borg Scale [29].
Figure 1 Study design: patients will be randomized in a 1:1 ratio between Arm 1 (standard radiotherapy) and Arm 2 (functional lung
avoidance radiotherapy).
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CT
Low dose, thoracic multi-detector row computed tom-
ography will be performed with the same breath-hold
volume and maneuver used for MRI. CT imaging will
be performed using a 64-slice (General Electric Health
Care, Milwaukee) scanner. In order to match CT and
MRI breath-hold volumes and anatomy, subjects will
be scanned in the supine position during inspiration
breath-hold from functional residual capacity (FRC) after
inhaling one litre of N2 gas as previously described [30].
MRI
MR imaging will be performed using a 3.0 T MR750
system (GE Health Care, Milwaukee, Wisconsin) using a
whole-body gradient amplitude of 1.94 G/cm and a single-
channel, rigid elliptical transmit/receive chest coil (Rapid
Biomedical GmbH, Wuerzburg, Germany). For 1H and 3He
MRI, subjects will be instructed to inhale from FRC a gas
mixture from a one-litre Tedlar bag (Jensen Inert Products,
Coral Springs, FL). Image acquisition will be performed
during a 16-second breath hold. Coronal (anatomical) 1H
MRI will be performed using the whole-body radiofre-
quency coil and 1H fast-spoiled, gradient-recalled echo se-
quence using a partial echo (16 s total data acquisition,
repetition time [TR] =4.7 ms, echo time [TE] =1.2 ms, flip
angle =30°, field of view =40 cm, bandwidth =24.4 kHz,
matrix =128 × 80, 15-17 slices, 15 mm slice thickness). 3He
MRI static ventilation images will be acquired using a fast-
gradient echo method using a partial echo (14 s total data
acquisition, TR/TE/flip angle =4.3 ms/1.4 ms/7°, field of
view =40 cm, bandwidth =48.8 kHz, matrix =128 × 80, 15-
17 slices, 15 mm slice thickness) [30]. A pulse oximeter
lead will be attached to all subjects to monitor their heart
rate and oxygen saturation. All subjects will have supple-
mental oxygen provided via nasal cannula at a flow rate of
two litres per minute during the scanning process.
Adverse events and pulse oximetry measurements
during MRI will be recorded. If oxygen saturation falls
to <80% continuously for ≥15 seconds, scanning will be
discontinued and the patient will be provided supple-
mental oxygen, as necessary, until oxygen saturation re-
covers to the patient’s baseline value. The patient will
then be discontinued from the study. Oxygen desatur-
ation below 88% during a 3He/129Xe breath-hold will be
considered an adverse event.
Radiotherapy
Technique
Patients will be treated with intensity modulated radiother-
apy (IMRT). Volumetric modulated arc therapy (VMAT) is
preferred, but IMRTcan be delivered using static-beam tech-
niques or other rotational techniques (e.g. Tomotherapy™).
For rotational techniques, care must be taken to minimize
dose to the contralateral lung. For each patient, both plans
(standard and functional-lung-avoidance) must be planned
using the same delivery technique. Respiratory gating is
allowed for tumours with >7 mm of respiratory motion.
Immobilization and localization
All patients will be positioned with arms over their heads,
chin extended and immobilized according to institutional
standards. Patients will undergo a planning 4DCT simula-
tion encompassing the entire lung volume, typically extend-
ing from level of the C5 to L1 (below diaphragm), with
3 mm slice thickness. Intravenous contrast may be used to
improve delineation of target volumes when the target is
centrally located, at the discretion of the treating radiation
oncologist. The planning CT may be fused with other avail-
able standard diagnostic imaging (MRI, CT or PET).
Functional lung delineation on planning CT
Pulmonary segmentation of ventilatory patterns will be
performed using semi-automated methods, as previously
described [22]. The 3He MRI containing the delineated
areas of functional lung will be fused to the breath-hold
CT and the planning CT. Due to differences in tidal vol-
ume between the two scans, deformable registration will
be required for most cases. To ensure accuracy, the fusion
will be inspected by a physicist and the treating physician.
Radiotherapy volume definitions
The radiotherapy planning and delivery parameters used
in this study are based on current consensus guidelines for
treatment of locally advanced lung cancer. The gross
tumour volume (GTV) is defined as the visible tumour
and involved lymph nodes based on CT or PET imaging
(nodes must be 1 cm or more in short axis or necrotic on
CT, or PET positive, or biopsy-proven to contain carcin-
oma). Elective nodal irradiation will not be used. Nodes
that are <1 cm and PET-negative may not be included in
the GTV unless they are necrotic-appearing.
Radiotherapy may be delivered using either a free-
breathing or a gated technique. For the free-breathing treat-
ment, a GTV will be delineated at end-inspiration and
end-expiration. At the discretion of the radiation oncolo-
gist, the GTV may also be delineated on other phases of
the breathing cycle (e.g. in cases involving significant hys-
teresis). All contoured GTVs shall then be fused to create
the internal GTV (IGTV). For patients treated with respira-
tory gating, a subset average CT will be created by aver-
aging several phases around end-expiration such that
tumour motion is minimized while maintaining a clinically-
acceptable gating window (typically, the 40-60% phases will
be used for the subset average). The GTV will be contoured
on the subset average scan and treatment will be delivered
within the defined gating window. The GTV may also be
contoured on the end-inspiration phase to aid in image-
guidance using free-breathing cone-beam CT.
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For all patients, a 5 mm margin will be added for
microscopic disease to create an Internal Target Volume
(ITV). This margin may be decreased at natural bound-
aries to microscopic extension (e.g. bone), or increased
up to 8 mm in areas of uncertainty. For the planning tar-
get volume (PTV), a further 5 mm expansion will be
added to the ITV in all directions.
For the purposes of radiotherapy planning, two venti-
lation regions will be created representing different
levels of lung ventilation. The structure LUNG-VENT
will represent lung with any measurable ventilation. The
structure LUNG-AVOID will represent lung tissue that
has normal ventilation according to previously published
methodology [23]. The structure LUNG-AVOID will be
preferentially spared. Due to registration errors and vari-
ous imaging artefacts, portions of the lung ventilation
maps are expected to be outside the anatomical lung
boundary of the planning CT. For this reason, lung ven-
tilation structures will be cropped so that they are con-
tained within the anatomically-defined lungs.
Prescription and dose constraints
The prescription dose will be 60 Gy in 30 fractions, with
95% of the PTV to receive 95% of the prescribed dose. Tar-
get dose constraints were adapted from the RTOG 0617
study protocol (Table 1) [31]. Normal structures including
spinal cord, right lung, left lung, oesophagus and heart
should be contoured on each CT slice of the planning CT.
The lung volume at risk is defined as the total lung minus
IGTV. The oesophagus should be contoured from the cau-
dal aspect of the cricoid to the gastroesophageal junction.
The heart contours should extend from the beginning of
the ascending aorta down to the apex of the heart.
The spinal cord dose constraint cannot be exceeded for
any reason. It is strongly recommended that the other
dose constraints not be exceeded. If any dose constraint
needs to be exceeded in order to achieve adequate cover-
age of the PTV, approval by the treating physician is
required.
Planning workflow and blinding
Before randomization, each patient will require two
clinically-approved treatment plans meeting the con-
straints defined above. One plan will be designed with-
out reference to the functional status of the lung
(termed standard plan). The second plan (termed avoid-
ance plan) will be optimized such that dose to functional
lung is as low as reasonably achievable, with an aim to
minimize the V5, V20, and mean dose within the func-
tional lung. For a given patient, both standard and avoid-
ance plans must use the same treatment technique, (i.e.
VMAT, static-gantry IMRT or Tomotherapy™). While
this protocol does allow for static-beam IMRT, a rota-
tional technique is preferred.
The standard plan will always be completed first,
followed by the avoidance plan. Avoidance plans will, in
general, be more heterogeneous than standard plans. While
homogeneous plans may be more aesthetically pleasing,
there is no evidence to suggest that they are superior. Thus,
PTV homogeneity constraints and conformity constraints
will be relaxed for avoidance plans. Nonetheless, hotspots
of 105% or greater will be avoided outside the PTV.
The structure LUNG-AVOID (representing normally-
ventilated lung) will be preferentially avoided in order to
devise the avoidance plan. In general, the anatomically-
defined lungs should not be used during optimization of
the avoidance plan; rather, the structure LUNG-VENT
should be used in its place. If necessary, a maximum
V20 constraint for the anatomical lungs may be used
which is the smaller of: 37%, or 3% greater than the V20
generated for the anatomical lungs in the standard plan.
Compared with the standard plan, the goals for the
avoidance plan will be as follows:
 3% reduction in the V20 for LUNG-AVOID, and/or
a 1.5% reduction in V20 for LUNG-VENT
 1.5 Gy drop in the mean dose to LUNG-AVOID, and/
or a 1 Gy reduction in mean dose to LUNG-VENT
 V20 and mean dose to the anatomical lungs should
be as similar as possible between the two plans
If these goals cannot be achieved, a decision will be
made by the physicist and the treating physician as to
whether the patient should be excluded from the trial.
Once both plans are deemed acceptable, the radiation
oncologist, dosimetrist, and physicist will review and ap-
prove both plans. When the radiation oncologist reviews
the two plans, machine parameters will be hidden; these
parameters will be viewable by the radiation oncologist
only after the randomization step (see below), and only
for the clinically-selected plan. To ensure consistency,
the two plans will have a V20 for the anatomically-
defined lungs (lung minus IGTV) within 3% of one an-
other. While there are no other explicit constraints for
Table 1 Normal tissue dose constraints for radiotherapy
planning
Structure Dose constraints for 60 Gy in 30 fractions
Spinal Cord Max dose <50 Gy
Lungs
V20 < 37%
V05 < 90%
Mean dose <21 Gy
Oesophagus
Mean dose <34 Gy
Minimize V60
Heart
60 Gy to <1/3
45 Gy to <2/3
40 Gy to <3/3
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the two plans relative to one-another, in the best clinical
judgment of the treating physician, neither plan should
be clearly superior in terms of either target coverage or
organ-at-risk (OAR) doses (excluding the anatomically-
defined lungs).
The doses to other OARs must be considered clinically
equivalent. Both plans will be printed and signed. The
patient will then be randomized (see randomization
below).
After randomization, one physicist (termed the ‘un-
blinded physicist’) will be responsible for receiving the
randomization results for all patients in this trial. This
unblinded physicist will choose the applicable plan for
clinical use. This will be labelled as “Clinical Plan” and
placed in the treatment system for standard quality as-
surance, and functional lung contours will be removed
from that plan to maintain blinding. The previous two
plans (standard and avoidance) will be archived under
password protection. The standard treatment binder will
include a printout of the clinical plan but will not con-
tain information that would allow for unblinding.
It is generally required that an unblinding procedure
be available in case of emergency. However, it is unlikely
that unblinding would be required under any circum-
stance, even in the event of a radiation complication, as
the doses delivered to normal structures will always be
available in the treatment binder, wherein the treatment
arm would not be apparent. In the unlikely event of an
unforeseen emergency where unblinding is required,
the unblinded physicist would be contacted and would
confirm with the radiation oncologist that unblinding is
required. That physicist would then access the password-
protected plan to determine which plan was selected. The
unblinded physicist will not be involved in patient care or
ascertainment of outcomes.
In the event that a patient should require a repeat CT
simulation for an unforeseen reason (e.g. pulmonary re-
expansion, new atelectasis, rapid reduction in tumour
bulk), the planning procedure above will be repeated,
with both a standard plan and an avoidance plan being
created. The unblinded physicist will not be involved in
any of the re-planning steps up until the randomization
step. Both re-plans (standard and avoidance) will need
to be approved by the radiation oncologist. At this point,
the unblinded physicist will select the appropriate plan
according to the previous randomization. The post-
randomization procedure will then continue as described
below.
Chemotherapy and treatment sequencing
Platinum-based chemotherapy will be delivered by the
medical oncologist according to local standards. Radio-
therapy will usually start with cycle 2 of chemotherapy.
However, at the discretion of the treating physician,
radiotherapy may be started with cycle 1 (urgent cases),
or after more than 2 cycles (e.g. where tumour downsiz-
ing is required). Concurrent chemotherapy cannot con-
tain taxanes or gemcitabine.
Follow-up and assessment of efficacy
Quality of life (QOL) and health utilities
QOL and health-utility data will be collected using the
FACT-L scale and the EQ-5D, respectively.
The primary QOL endpoint will be based on the FACT-
LCS (a subset of FACT-L) which measures pulmonary
QOL specifically. As a secondary endpoint, the FACT-TOI
incorporates the LCS with two additional domains from
FACT-L: the Physical Well Being (PWB) and Functional
Well-Being (FWB) scores. Although only subsets of FACT-
L are used for these two endpoints, it is generally recom-
mended that the full FACT-L be completed during clinical
trials for more robust assessment of other QOL domains.
The EQ-5D measures health utility, and is used for
calculating quality-adjusted survival and cost-utility.
Follow-up
Patients will be assessed by the radiation oncologist at
3 months, 6 months and 1 year, then every 6 months until
two years, then annually until 5 years (Table 2). A detailed
history, physical examinations and CT chest and upper ab-
domen will be performed with each assessment. Other in-
vestigations are as follows:
 Toxicity scoring and QOL scoring (FACT-L and
EQ-5D): during the last week of radiotherapy (i.e. at
last patient review clinical visit), and at 3-, 6- and
12-months post-treatment.
 Pulmonary Function Tests and 6MWT: 3-months
and 12-months post-treatment
Statistics and sample size calculation
Sample size
The primary endpoint is the QOL score on the FACT-LCS
measured 3-months post-treatment. A change in the LCS
score of 2-3 points is considered clinically relevant [32].
Following concurrent CRT, it is assumed that in the arm re-
ceiving standard treatment, the mean post-treatment LCS
score will be 20 [33]. The study will use a two-sided,
independent-sample t-test with an alpha level of 0.05 and
power of 80%, and will assume a 3-month QOL non-
completion rate of 10%. The standard deviation of the LCS
score is estimated to be 4. In order to detect a 3-point im-
provement in QOL in the experimental arm (Arm 2), a
total of 64 patients will be required (32 in each arm).
Randomization
Randomization will occur in a 1:1 ratio between Arm 1
and Arm 2 using permuted blocks. Randomization results
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will be communicated by the statistician to the unblinded
physicist by telephone.
Analysis plan
Patients will be analysed in the groups to which they are
assigned (intention-to-treat). An independent-sample t-
test will be used to compare QOL scores at 3-months.
The percentage of patients in each arm who experience
a clinically significant QOL decline (3 points) will also
be reported. Survival will be calculated from date of
randomization using the Kaplan-Meier method with dif-
ferences compared using the log-rank test. A Cox multi-
variable regression analysis will be used to determine
baseline factors predictive of survival. For the secondary
endpoints involving QOL scales, linear mixed effects
models will be used.
Data safety monitoring committee
The data safety monitoring committee (DSMC) will con-
sist of a statistician, an independent investigator, and a
content expert. The DSMC will review toxicity outcomes
on a semi-annual basis. If any grade 3-5 toxicity is re-
ported, the patient case will be reviewed to determine if
such toxicity is related to treatment. The DSMC may rec-
ommend modification or cessation of the trial if radiother-
apy toxicity rates are deemed excessive (e.g. >10% grade 5
toxicity).
Interim analysis
The DSMC will conduct one interim analysis once 32
patients have been accrued and followed for 3 months.
For this analysis, the DSMC will be blinded to the iden-
tity of each treatment arm, but QOL and OS data will
be presented for each arm.
The DSMC will recommend stopping the trial if there
is an OS difference that is statistically significant with a
threshold of p < 0.001 using the log-rank test, based on
the Haybittle-Peto stopping rule. This retains an overall
alpha of 0.05.
At the Interim Analysis, the DSMC will also check the
validity of the sample size calculation assumptions. The
DSMC will be provided with the standard deviation of the
FACT-LCS scores in each arm (while remaining blinded
to the identity of each arm), and the rate of completion of
the 3-month QOL forms. If these values are substantially
different than estimated in the sample size calculation, the
DSMC can recommend increasing or decreasing the tar-
get accrual in order to maintain statistical power.
Institutional research ethics board (REB) approval
Western University REB Number: 104834 transferred
under methods section.
Discussion
The goal of this randomized, double-blind trial is to
comprehensively evaluate the effect of functional lung
avoidance using pulmonary functional imaging on both
pulmonary toxicity and QOL, specifically for patients re-
ceiving concurrent CRT for locally advanced NSCLC.
To date, SPECT and 4DCT have been used in radi-
ation treatment planning to provide functional lung in-
formation. These investigations have demonstrated the
reduction of dose to healthy lung tissue [11,16]. How-
ever, to our knowledge, they have not assessed patient
QOL as one of their primary endpoints, which has dem-
onstrated to be a powerful tool to capture pulmonary
toxicity outcomes [9].
Hyperpolarized 3He MRI provides an alternative to
SPECT and 4DCT and offers high spatial and temporal
resolution of respiratory function [15]. Although 3He has
several inherent advantages, it will not likely achieve wide-
spread clinical use, due to cost and a limited global supply
of helium. However, several alternatives appear promising
and are expected to be available for widespread clinical
use in the future, including 129Xe MRI and 1H Fourier De-
composition, which are currently less well-developed than
3He MRI and 4DCT. By establishing the benefits of 3He
MRI functional lung avoidance and validating it against
less developed methods such as 129Xe and 1H Fourier De-
composition MRI, these latter methods will allow for
widespread implementation of functional lung avoidance
radiotherapy.
Table 2 Follow-up schedule
Before
entry
Last week of
radiotherapy
Month
3
Month
6
Bianually for 2 years then
annually until year 5
History and Physical X X X X X
Staging Imaging (see section 5) X
Pulmonary function tests and 6MWT at Robarts Research
Institute
X X X
Baseline Bloodwork (see section 5) X
Pregnancy test for women of child-bearing age X
Toxicity and QOL Scoring (PAR, FACT-L, EQ-5D) X X X X X (month 12 only)
Follow-up CT chest/upper abdomen X X X
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In summary, this study will determine if 3He MRI-
based functional lung avoidance methods will improve
QOL and pulmonary toxicity in subjects with unresect-
able NSCLC.
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